CHL Medical Partners

Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

CareWell Urgent Care is a provider of emergency healthcare services based in Tewksbury, Massachusetts, with multiple centers operating in the New England area. The organization focuses on delivering accessible and efficient urgent care for a variety of common illnesses and injuries, including cold infections, fractures, rashes, nosebleeds, chronic conditions, and skin diseases. CareWell Urgent Care offers on-site laboratory services, X-ray capabilities, and the ability to dispense common medications, enabling patients to receive timely treatment without the need for an appointment.

Ambra Health is a medical data and image management company that provides a cloud-based platform designed to enhance the accessibility and management of medical images. The platform is intuitive, flexible, and scalable, enabling healthcare providers, including prominent health systems and clinical research organizations, to improve their imaging workflows and collaborative care. By offering secure and straightforward access to medical images, Ambra Health facilitates better internal adoption and collaboration among healthcare professionals. This capability allows organizations to significantly enhance their operational efficiency and patient care outcomes by making medical images and data accessible from anywhere.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to combat infectious diseases in the United States and internationally. The company offers a range of products, including the Acuitas AMR Gene Panel for detecting bacterial nucleic acids and genetic markers of antimicrobial resistance, as well as QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to enhance management of multidrug-resistant organisms (MDROs). OpGen collaborates with the New York State Department of Health to devise solutions for tracking and managing antimicrobial-resistant infections in healthcare settings. Founded in 2001 and based in Gaithersburg, Maryland, the company aims to improve patient outcomes and reduce the spread of infections through rapid and actionable diagnostic information.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative drug delivery solutions for patients with Type 2 diabetes. The company's primary product was the V-Go, a disposable insulin delivery device designed for continuous basal and on-demand bolus dosing, aimed at simplifying insulin management for users. Valeritas also worked on the V-Go Prefill, intended to streamline the device-filling process, and the V-Go SIM, which provided real-time tracking of insulin dosing. Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas sold its products through third-party wholesalers and medical supply distributors. However, the company filed for Chapter 11 bankruptcy on June 30, 2020, ceasing operations.

Ambra Health is a medical data and image management company that provides a cloud-based platform designed to enhance the accessibility and management of medical images. The platform is intuitive, flexible, and scalable, enabling healthcare providers, including prominent health systems and clinical research organizations, to improve their imaging workflows and collaborative care. By offering secure and straightforward access to medical images, Ambra Health facilitates better internal adoption and collaboration among healthcare professionals. This capability allows organizations to significantly enhance their operational efficiency and patient care outcomes by making medical images and data accessible from anywhere.

Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to combat infectious diseases in the United States and internationally. The company offers a range of products, including the Acuitas AMR Gene Panel for detecting bacterial nucleic acids and genetic markers of antimicrobial resistance, as well as QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to enhance management of multidrug-resistant organisms (MDROs). OpGen collaborates with the New York State Department of Health to devise solutions for tracking and managing antimicrobial-resistant infections in healthcare settings. Founded in 2001 and based in Gaithersburg, Maryland, the company aims to improve patient outcomes and reduce the spread of infections through rapid and actionable diagnostic information.

Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis (LSS). Founded in 2005 and headquartered in Aliso Viejo, California, the company has developed the mild device, which provides an outpatient, fluoroscopically guided treatment for LSS without the need for implants. This innovative approach allows physicians to perform lumbar decompression procedures under local anesthesia, helping to restore space in the spinal canal, alleviate pressure on nerves, and enhance patient mobility. Vertos Medical's commitment to advancing spinal care is reflected in its focus on delivering effective solutions for common spinal diseases.

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis (LSS). Founded in 2005 and headquartered in Aliso Viejo, California, the company has developed the mild device, which provides an outpatient, fluoroscopically guided treatment for LSS without the need for implants. This innovative approach allows physicians to perform lumbar decompression procedures under local anesthesia, helping to restore space in the spinal canal, alleviate pressure on nerves, and enhance patient mobility. Vertos Medical's commitment to advancing spinal care is reflected in its focus on delivering effective solutions for common spinal diseases.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

North American Scientific is engaged in the design, development, manufacture, and sale of radioisotopic products for the treatment of cancer. The company offers Prospera I-125, an iodine-based seed and Prospera Pd-103, a palladium-based seed for the treatment of prostate cancer; SurTRAK needles and strands used primarily for the treatment of prostate cancer; and STP-110 Precision Stepper and RTP-6000 Precision Stabilizer equipment, which positions and holds the trans-rectal ultrasound probe during the LDR brachytherapy procedure as well as radiation shielding and needle loading accessories such as horizontal needle box; and needle-loading shield, box, and carousel. The company also offers ClearPath, a multi-catheter breast brachytherapy device for accelerated partial breast irradiation treatment for women with early-stage breast cancer. North American Scientific was founded in 1987 and is based in Chatsworth, California, United States.

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

BIKAM Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. BIKAM's research centers on small molecule, non-retinoid pharmacological chaperones designed to address issues related to misfolded proteins within the retina. Their lead product is an orally active pharmacological chaperone that targets misfolded rod opsin, which is implicated in retinitis pigmentosa, helping to correct its trafficking to the rod cell surface and outer segment. Through its innovative approach, BIKAM Pharmaceuticals strives to provide new treatment options for patients suffering from these serious retinal conditions.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to combat infectious diseases in the United States and internationally. The company offers a range of products, including the Acuitas AMR Gene Panel for detecting bacterial nucleic acids and genetic markers of antimicrobial resistance, as well as QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to enhance management of multidrug-resistant organisms (MDROs). OpGen collaborates with the New York State Department of Health to devise solutions for tracking and managing antimicrobial-resistant infections in healthcare settings. Founded in 2001 and based in Gaithersburg, Maryland, the company aims to improve patient outcomes and reduce the spread of infections through rapid and actionable diagnostic information.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Ascend Health Corporation is a behavioral healthcare provider that specializes in a comprehensive range of inpatient and day hospital services for individuals across various age groups, including children, adolescents, adults, and seniors. The organization operates freestanding psychiatric hospitals and offers a wide array of behavioral health programs, such as residential treatment centers, partial hospitalization, and intensive outpatient services. Ascend Health emphasizes personal choice and tailored care, ensuring that its services are effectively integrated with the local healthcare systems to deliver high-quality treatment for mental health and substance abuse issues.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Amicus Therapeutics is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. The company is known for its product Galafold, an orally administered small molecule pharmacological chaperone specifically designed for treating Fabry disease. Amicus is also advancing its clinical pipeline, including a Phase 3 study of AT-GAA for Pompe disease. The company focuses on creating novel therapies, particularly pharmacological chaperones, which are intended to stabilize and enhance the activity of misfolded enzymes in patients. This approach may improve treatment outcomes, especially when used in conjunction with enzyme replacement therapy. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey, collaborating with institutions like Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Cantex Pharmaceuticals is a biotechnology company focused on developing innovative cancer treatments by modifying existing therapies. The company has two primary development programs that utilize known chemical entities to address significant unmet medical needs in oncology. One of its key products is ODSH, a low anticoagulant heparin derivative aimed at mitigating the adverse effects of chemotherapy on platelet counts. Additionally, Cantex offers Disulfiram-Copper Chelate, which employs multiple mechanisms to target cancer stem cells, making it a potential treatment option for metastatic breast cancer, pancreatic cancer, and glioblastoma. Established in 2002 and based in Weston, Florida, Cantex Pharmaceuticals is dedicated to creating safer and more effective therapeutic options for patients facing life-threatening disorders.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Oculir develops non-invasive glucose meter that measures glucose from the conjunctiva of the eye.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Millennium Pharmacy Systems is a pharmacy services provider focused on the long-term care industry. Headquartered in Chicago, Illinois, the company offers a unique approach to pharmacy services by integrating Just-In-Time Dispensing with electronic prescription ordering, formulary management, and comprehensive medication administration. This combination enables nursing and assisted living communities to enhance patient care while effectively reducing costs and improving operational efficiency. Millennium's commitment to timely delivery and medication accuracy is reflected in its customer guarantees, supporting clients in meeting compliance requirements more easily.

Amicus Therapeutics is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. The company is known for its product Galafold, an orally administered small molecule pharmacological chaperone specifically designed for treating Fabry disease. Amicus is also advancing its clinical pipeline, including a Phase 3 study of AT-GAA for Pompe disease. The company focuses on creating novel therapies, particularly pharmacological chaperones, which are intended to stabilize and enhance the activity of misfolded enzymes in patients. This approach may improve treatment outcomes, especially when used in conjunction with enzyme replacement therapy. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey, collaborating with institutions like Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

GeneOhm Sciences is a company that designs, develops, and delivers nucleic acid-based diagnostic solutions aimed at addressing unmet diagnostic needs across various diseases, including inherited diseases, infectious diseases, and oncology. Based in San Diego, California, and established in 2001, GeneOhm focuses on developing rapid diagnostic systems that can detect and identify infectious agents and genetic variations, providing results in under two hours. The company offers specific diagnostic tests, including an assay for methicillin-resistant Staphylococcus aureus (MRSA) and a test for Group B Streptococcus in pregnant women. Additionally, GeneOhm's technology includes a lysis kit for processing various sample types. In 2004, GeneOhm merged with Infectio Diagnostic, Inc., enhancing its portfolio with proprietary technology and industry expertise. The company was later acquired by the BD Pharmaceuticals group, further solidifying its position in the molecular diagnostics field.

Amicus Therapeutics is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. The company is known for its product Galafold, an orally administered small molecule pharmacological chaperone specifically designed for treating Fabry disease. Amicus is also advancing its clinical pipeline, including a Phase 3 study of AT-GAA for Pompe disease. The company focuses on creating novel therapies, particularly pharmacological chaperones, which are intended to stabilize and enhance the activity of misfolded enzymes in patients. This approach may improve treatment outcomes, especially when used in conjunction with enzyme replacement therapy. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey, collaborating with institutions like Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Eunoe, Inc. is a San Francisco Bay-area medical device company focused on the treatment of neurological disorders through the management of cerebrospinal fluid.

LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.

Amicus Therapeutics is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. The company is known for its product Galafold, an orally administered small molecule pharmacological chaperone specifically designed for treating Fabry disease. Amicus is also advancing its clinical pipeline, including a Phase 3 study of AT-GAA for Pompe disease. The company focuses on creating novel therapies, particularly pharmacological chaperones, which are intended to stabilize and enhance the activity of misfolded enzymes in patients. This approach may improve treatment outcomes, especially when used in conjunction with enzyme replacement therapy. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey, collaborating with institutions like Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

RxCentric is an e-health business-to-business company linking physicians' drug information and education needs with a targeted, online.

RxCentric is an e-health business-to-business company linking physicians' drug information and education needs with a targeted, online.

Protometrix develops integrated proteomics technologies to improve human health. Protometrix focuses on the production and investigation of the function and interaction of proteins in parallel using nanoscale technology and collection of information in an informatics database.

Molecular Staging, Inc. is a life sciences tool company focused on developing technologies for the detection and measurement of proteins and nucleic acids. Its offerings encompass various applications in proteomics, genomics, pharmacogenomics, and diagnostics. Notable products include protein microarrays, which allow researchers to analyze multiple proteins simultaneously, and whole-genome amplification technology that addresses challenges posed by limited DNA sample quantities. Additionally, the company provides multiplexed diagnostics, facilitating the earlier detection of diseases and enhancing confirmatory diagnoses. Through these innovations, Molecular Staging supports advancements in research and clinical applications.

Lifespire was created in late 1999 through the merging of 2 companies: Vida Healthcare and inspiria.com. Vida Healthcare, formed in 1996, has worked with hundreds of oncology doctors, nurses and allied health professionals to improve cancer care. Lifespire Their vision is to improve care through shared knowledge. But what does that mean to you, the patient, and your circle of family and friends They serve? It means that They are giving you and the ones closest to you -- your circle of care -- a resource for gathering credible knowledge, support and understanding of your experience with cancer. Some of you may have known us when They were Vida Healthcare. In Their four years as Vida, They delivered clinical support and education services to over 4,000 people experiencing cancer. Now They're bringing that experience and understanding to you. They're doing this in partnership with companies committed to improving the treatment of cancer. And They're using Lifespire.com as Their forum for delivery.

RxCentric is an e-health business-to-business company linking physicians' drug information and education needs with a targeted, online.

ICOS Corporation is a biotechnology company that engages in the discovery, development, and commercialization of therapeutic products. It is engaged in the commercialization of treatments for unmet medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. It is the developer of a treatment known as Cialis (tadalafil), a product for the treatment of erectile dysfunction through its joint venture with Eli Lilly and Company in North America and Europe. It is also engaged in contract manufacturing services for third parties. It is in a strategic alliance with Solvay Pharmaceuticals, Inc. ICOS Corporation was established in 1989, based in Bothell, Washington. It is currently operated by Eli Lilly and Company.